Einzeltreffer — DigiBib

A safe and effective vaccine with long-term protection against SARS-CoV-2 variants of concern (VOCs) is a global health priority. Here, we develop lipid nanoparticles (LNPs) to provide safe and effective delivery of plasmid DNA (pDNA) and show protection against VOCs in female small animal models. Using a library of LNPs encapsulating unique barcoded DNA (b-DNA), we screen for b-DNA delivery after intramuscular administration. The top-performing LNPs are further tested for their capacity of pDNA uptake in antigen-presenting cells in vitro. The lead LNP is used to encapsulate pDNA encoding the HexaPro version of SARS-CoV-2 spike (LNP-HPS) and immunogenicity and protection is tested in vivo. LNP-HPS elicit a robust protective effect against SARS-CoV-2 Gamma (P.1), correlating with reduced lethality, decreased viral load in the lungs and reduced lung damage. LNP-HPS induce potent humoral and T cell responses against P.1, and generate high levels of neutralizing antibodies against P.1 and Omicron (B.1.1.529). Our findings indicate that the protective efficacy and immunogenicity elicited by LNP-HPS are comparable to those achieved by the approved COVID-19 vaccine from Biontech/Pfizer in animal models. Together, these findings suggest that LNP-HPS hold great promise as a vaccine candidate against VOCs.

Titel:	Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models.
Autor/in / Beteiligte Person:	Guimaraes, LC ; Costa, PAC ; Scalzo Júnior, SRA ; Ferreira, HAS ; Braga, ACS ; de Oliveira LC ; Figueiredo, MM ; Shepherd, S ; Hamilton, A ; Queiroz-Junior, CM ; da Silva WN ; da Silva NJA ; Rodrigues Alves, MT ; Santos, AK ; de Faria KKS ; Marim, FM ; Fukumasu, H ; Birbrair, A ; Teixeira-Carvalho, A ; de Aguiar RS ; Mitchell, MJ ; Teixeira, MM ; Vasconcelos Costa, V ; Frezard, F ; Guimaraes, PPG
Link:	Zum Volltext
Zeitschrift:	Nature communications, Jg. 15 (2024-01-18), Heft 1, S. 590
Veröffentlichung:	[London] : Nature Pub. Group, 2024
Medientyp:	academicJournal
ISSN:	2041-1723 (electronic)
DOI:	10.1038/s41467-024-44830-1
Schlagwort:	Female Animals Humans SARS-CoV-2 genetics Nanovaccines COVID-19 Vaccines DNA Antibodies, Neutralizing Antibodies, Viral Vaccines, DNA genetics DNA, B-Form COVID-19 prevention & control
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Nat Commun] 2024 Jan 18; Vol. 15 (1), pp. 590. <i>Date of Electronic Publication: </i>2024 Jan 18. MeSH Terms: Vaccines, DNA* / genetics ; DNA, B-Form* ; COVID-19* / prevention & control ; Female ; Animals ; Humans ; SARS-CoV-2 / genetics ; Nanovaccines ; COVID-19 Vaccines ; DNA ; Antibodies, Neutralizing ; Antibodies, Viral References: Nat Med. 2023 Feb;29(2):348-357. (PMID: 36652990) ; JAMA Cardiol. 2021 Oct 1;6(10):1196-1201. (PMID: 34185046) ; Cell. 2021 Apr 29;184(9):2372-2383.e9. (PMID: 33743213) ; Lancet. 2022 Apr 2;399(10332):1313-1321. (PMID: 35367003) ; Cell. 2021 Apr 29;184(9):2384-2393.e12. (PMID: 33794143) ; Cell Rep. 2022 Feb 15;38(7):110387. (PMID: 35134331) ; Nat Immunol. 2022 Feb;23(2):186-193. (PMID: 35105982) ; Sci Transl Med. 2021 Jan 20;13(577):. (PMID: 33288662) ; N Engl J Med. 2022 Feb 3;386(5):492-494. (PMID: 34965337) ; Science. 2021 Oct 22;374(6566):eabj9853. (PMID: 34519540) ; Int J Nanomedicine. 2023 Oct 18;18:5891-5904. (PMID: 37873551) ; Nat Rev Microbiol. 2023 Mar;21(3):162-177. (PMID: 36653446) ; Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):2060-2065. (PMID: 28167778) ; Lancet. 2022 Apr 2;399(10332):1281-1282. (PMID: 35366995) ; JAMA Netw Open. 2021 Jun 1;4(6):e2114531. (PMID: 34170306) ; Nat Biomed Eng. 2020 Nov;4(11):1076-1089. (PMID: 33020600) ; Nat Nanotechnol. 2021 Apr;16(4):369-384. (PMID: 33753915) ; Sci Rep. 2022 Dec 3;12(1):20923. (PMID: 36463322) ; Cell Rep Med. 2021 Jul 20;2(7):100355. (PMID: 34230917) ; J Control Release. 2022 May;345:819-831. (PMID: 35346768) ; Science. 2020 Sep 18;369(6510):1501-1505. (PMID: 32703906) ; Nat Nanotechnol. 2022 Oct;17(10):1027-1037. (PMID: 35982317) ; Lancet. 2022 Jun 11;399(10342):2168-2169. (PMID: 35691306) ; Immunity. 2021 Dec 14;54(12):2877-2892.e7. (PMID: 34852217) ; Int J Nanomedicine. 2022 Jun 30;17:2865-2881. (PMID: 35795081) ; NPJ Vaccines. 2021 Dec 20;6(1):156. (PMID: 34930909) ; N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609) ; Nature. 2023 Feb;614(7946):22-25. (PMID: 36726000) ; Nature. 2021 Sep;597(7875):161-162. (PMID: 34475553) ; Nat Immunol. 2022 Apr;23(4):543-555. (PMID: 35288714) ; Curr Res Transl Med. 2022 Sep;70(4):103348. (PMID: 35489099) ; Pediatrics. 2021 Sep;148(3):. (PMID: 34088762) ; NPJ Vaccines. 2021 Oct 14;6(1):121. (PMID: 34650089) ; Nat Commun. 2022 Nov 4;13(1):6644. (PMID: 36333374) ; Nat Commun. 2020 May 20;11(1):2601. (PMID: 32433465) ; Nat Rev Drug Discov. 2021 Nov;20(11):817-838. (PMID: 34433919) ; N Engl J Med. 2021 Sep 30;385(14):1332-1334. (PMID: 34407340) ; Nature. 2022 Mar;603(7902):700-705. (PMID: 35104835) ; NPJ Vaccines. 2022 Apr 26;7(1):49. (PMID: 35474311) ; J Control Release. 2019 Dec 28;316:404-417. (PMID: 31678653) ; Expert Rev Vaccines. 2021 Dec;20(12):1549-1560. (PMID: 34582298) ; Nat Med. 2023 Feb;29(2):344-347. (PMID: 36473500) ; N Engl J Med. 2021 Mar 17;384(15):1468-1470. (PMID: 33730471) ; Science. 2020 Aug 14;369(6505):806-811. (PMID: 32434945) ; Nature. 2022 Mar;603(7902):687-692. (PMID: 35062015) ; Commun Med (Lond). 2022 Apr 13;2:41. (PMID: 35603276) ; Proc Natl Acad Sci U S A. 2023 Jun 20;120(25):e2215711120. (PMID: 37310997) ; Vaccine. 2021 Jul 5;39(30):4108-4116. (PMID: 34120764) ; N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246) ; Nat Commun. 2022 Sep 30;13(1):5760. (PMID: 36180438) ; Proc Natl Acad Sci U S A. 2021 Dec 28;118(52):. (PMID: 34933999) ; Nat Rev Drug Discov. 2019 Mar;18(3):175-196. (PMID: 30622344) Grant Information: 401390/2020-9 Ministry of Science, Technology and Innovation \| Conselho Nacional de Desenvolvimento Científico e Tecnológico (National Council for Scientific and Technological Development); 442731/2020-5 Ministry of Science, Technology and Innovation \| Conselho Nacional de Desenvolvimento Científico e Tecnológico (National Council for Scientific and Technological Development); 305932/2022-5 Ministry of Science, Technology and Innovation \| Conselho Nacional de Desenvolvimento Científico e Tecnológico (National Council for Scientific and Technological Development); 422002/2023-2 Ministry of Science, Technology and Innovation \| Conselho Nacional de Desenvolvimento Científico e Tecnológico (National Council for Scientific and Technological Development); 408482/2022-2 Ministry of Science, Technology and Innovation \| Conselho Nacional de Desenvolvimento Científico e Tecnológico (National Council for Scientific and Technological Development) Substance Nomenclature: 0 (Vaccines, DNA) ; 0 (Nanovaccines) ; 0 (DNA, B-Form) ; 0 (COVID-19 Vaccines) ; 9007-49-2 (DNA) ; 0 (Antibodies, Neutralizing) ; 0 (Antibodies, Viral) SCR Organism: SARS-CoV-2 variants Entry Date(s): Date Created: 20240118 Date Completed: 20240122 Latest Revision: 20240122 Update Code: 20240122 PubMed Central ID: PMC10796936

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models.